Literature DB >> 21454981

Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.

Murat Yildiz, Barbara Tettenborn, Norman Putzki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21454981     DOI： 10.1159/000324028

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


× No keyword cloud information.
  10 in total

1.  Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.

Authors:  John N Ratchford; Regina Brock-Simmons; Amanda Augsburger; Sonya U Steele; Kristie Mohn; Mandi Rhone; Jinyan Bo; Kathleen Costello
Journal:  Int J MS Care       Date:  2014

2.  Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study.

Authors:  Jeffrey Wilken; Robert L Kane; Cynthia L Sullivan; Mark Gudesblatt; Sylvia Lucas; Robert Fallis; Xiaojun You; Pam Foulds
Journal:  Int J MS Care       Date:  2013

3.  Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls.

Authors:  Andrea T White; Alan R Light; Ronald W Hughen; Timothy A Vanhaitsma; Kathleen C Light
Journal:  Psychosom Med       Date:  2011-12-30       Impact factor: 4.312

Review 4.  Inflammation and the Silent Sequelae of Stroke.

Authors:  Kyra J Becker
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

Review 5.  Fatigue as a symptom or comorbidity of neurological diseases.

Authors:  Iris-Katharina Penner; Friedemann Paul
Journal:  Nat Rev Neurol       Date:  2017-10-13       Impact factor: 42.937

6.  Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.

Authors:  Pietro Iaffaldano; Rosa Gemma Viterbo; Damiano Paolicelli; Guglielmo Lucchese; Emilio Portaccio; Benedetta Goretti; Vita Direnzo; Mariangela D'Onghia; Stefano Zoccolella; Maria Pia Amato; Maria Trojano
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

Review 7.  The representation of inflammatory signals in the brain - a model for subjective fatigue in multiple sclerosis.

Authors:  Katrin Hanken; Paul Eling; Helmut Hildebrandt
Journal:  Front Neurol       Date:  2014-12-11       Impact factor: 4.003

Review 8.  Is there a link between inflammation and fatigue in multiple sclerosis?

Authors:  Moussa A Chalah; Samar S Ayache
Journal:  J Inflamm Res       Date:  2018-06-07

Review 9.  Multiple sclerosis-related fatigue lacks a unified definition: A narrative review.

Authors:  Iman Adibi; Mehdi Sanayei; Farinaz Tabibian; Neda Ramezani; Ahmad Pourmohammadi; Kiarash Azimzadeh
Journal:  J Res Med Sci       Date:  2022-03-17       Impact factor: 1.852

10.  Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.

Authors:  Anders Svenningsson; Eva Falk; Elisabeth G Celius; Siegrid Fuchs; Karen Schreiber; Sara Berkö; Jennifer Sun; Iris-Katharina Penner
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.